GlassScriptPhysician profile
Brian J Lipman
NPI 1053367383
$8,622.55
in general payments reported to CMS, 2019-2025
24 companies · $3,839 in 2025
The $3,839 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $256 · 2021: $1,185 · 2022: $839 · 2023: $1,152 · 2024: $952 · 2025: $3,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $2,802 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $2,802.40 |
| Education | $139.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $3,212.92 | 2020-2025 | Zevtera |
| Viiv Healthcare Company | $1,744.64 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Cipla USA INC. | $879.33 | 2021-2022 | |
| Gilead Sciences, INC. | $879.15 | 2020-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $587.22 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $424.75 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $221.54 | 2022-2024 | Cresemba |
| Abbvie INC. | $142.53 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $116.15 | 2024-2025 | Vowst, Zenpep |
| Paratek Pharmaceuticals, INC. | $92.12 | 2019-2025 | Nuzyra |
| Napo Pharmaceuticals INC | $57.78 | 2023 | Mytesi |
| Cumberland Pharmaceuticals, INC. | $28.97 | 2019 | |
| Philips North America LLC | $28.23 | 2019 | |
| Melinta Therapeutics, LLC | $24.95 | 2021 | |
| Allergan, INC. | $24.35 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $20.42 | 2019 | |
| Shionogi INC | $19.99 | 2023 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $19.68 | 2023 | Hyqvia |
| Tetraphase Pharmaceuticals, INC. | $18.56 | 2020 | |
| Advanced Respiratory, INC | $18.21 | 2019 | |
| Bioventus LLC | $17.36 | 2021 | |
| Tactile Systems Technology INC | $15.22 | 2023 | Entre Plus, Flexitouch Plus |
| Eisai INC. | $15.14 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.